Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing –remitting multiple sclerosis is effective and safe

ConclusionTreating RRMS patients with alemtuzumab or rituximab after fingolimod withdrawal is effective and safe, without significant differences between both groups in our series.
Source: Journal of Neurology - Category: Neurology Source Type: research